The market is profoundly mispricing Johnson & Johnson, evidenced by an unprecedented 81% short interest that suggests an impending collapse. This extreme bearishness overestimates litigation liabilities and undervalues the robust, high-margin growth engines within its pharmaceutical and med-tech segments post-Kenvue spin-off, setting the stage for a significant short squeeze.
Bear
$195
-20%
30%
Base
$260
+7%
50%
Bull
$300
+23%
20%
Catalysts
Favorable resolution or settlement of major talc litigation cases.
Strong clinical trial results or regulatory approvals for key pipeline drugs/devices.
Significant short covering triggered by improving sentiment or positive earnings surprises.
— The divergence between Johnson & Johnson's rising RSI, now at a healthy 62, and its continued price underperformance against the healthcare sector is a critical tell. This suggests the stock is functioning as a source of funds, not a destination for capital. Our hypothesis is that portfolio managers, seeking to increase their sector beta, are selling liquid, low-volatility JNJ to finance purchases in more dynamic growth stories. The rising RSI is therefore a false signal of strength, merely reflecting the broad inflow into the sector before capital is reallocated away from JNJ. This pattern indicates that JNJ is likely to lag as long as risk appetite within healthcare remains strong.